Jump to content

Olorinab

Edit links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Boghog (talk | contribs) at 13:47, 14 September 2018 (templated cites). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Olorinab
Clinical data
Routes of
administration		Oral
Identifiers
  • (4aS,5aS)-N-((2S)-1-hydroxy-3,3-dimethylbutan-2-yl)-1-(4-oxidopyrazin-2-yl)-4,4a,5,5a-tetrahydro-1H-cyclopropa(4,5)cyclopenta[1,2-c]pyrazole-3-carboxamide
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H24N5O3
Molar mass358.414 g/mol g·mol−1
3D model (JSmol)
  • CC(C)(C)[C@@H](CO)NC(=O)C1=NN(C2=C1C[C@H]3[C@@H]2C3)C4=NC=C[N+](=C4)[O-]
  • InChI=1S/C18H23N5O3/c1-18(2,3)13(9-24)20-17(25)15-12-7-10-6-11(10)16(12)23(21-15)14-8-22(26)5-4-19-14/h4-5,8,10-11,13,24H,6-7,9H2,1-3H3,(H,20,25)/t10-,11-,13+/m0/s1
  • Key:ACSQLTBPYZSGBA-GMXVVIOVSA-N

Olorinab (APD371) is a drug developed by Arena Pharmaceuticals for the treatment of pain associated with Crohn's disease. It acts as a potent and selective cannabinoid CB2 receptor agonist and is claimed to be orally active and peripherally selective, and has progressed to Phase II clinical trials.[1][2]

See also


References

  1. ^ Han S, Thoresen L, Jung JK, Zhu X, Thatte J, Solomon M, et al. (December 2017). "Discovery of APD371: Identification of a Highly Potent and Selective CB2 Agonist for the Treatment of Chronic Pain". ACS Medicinal Chemistry Letters. 8 (12): 1309–1313. doi:10.1021/acsmedchemlett.7b00396. PMID 29259753.
  2. ^ "Olorinab (APD371)". Arena Pharmaceuticals, Inc.
Stub icon

This cannabinoid related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Olorinab&oldid=859509160"